258 related articles for article (PubMed ID: 10810390)
1. Promoter specific sensitivity to inhibition of histone deacetylases: implications for hormonal gene control, cellular differentiation and cancer.
Dressel U; Renkawitz R; Baniahmad A
Anticancer Res; 2000; 20(2A):1017-22. PubMed ID: 10810390
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation.
Law AY; Lai KP; Lui WC; Wan HT; Wong CK
Exp Cell Res; 2008 Oct; 314(16):2975-84. PubMed ID: 18652825
[TBL] [Abstract][Full Text] [Related]
3. Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activity.
Klan N; Seuter S; Schnur N; Jung M; Steinhilber D
Biol Chem; 2003 May; 384(5):777-85. PubMed ID: 12817474
[TBL] [Abstract][Full Text] [Related]
4. E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer.
Lu Z; Luo RZ; Peng H; Huang M; Nishmoto A; Hunt KK; Helin K; Liao WS; Yu Y
Oncogene; 2006 Jan; 25(2):230-9. PubMed ID: 16158053
[TBL] [Abstract][Full Text] [Related]
5. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
Zhang Y; Fatima N; Dufau ML
Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MMTV transcription by HDAC inhibitors occurs independent of changes in chromatin remodeling and increased histone acetylation.
Mulholland NM; Soeth E; Smith CL
Oncogene; 2003 Jul; 22(31):4807-18. PubMed ID: 12894222
[TBL] [Abstract][Full Text] [Related]
7. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells.
Zhao S; Venkatasubbarao K; Li S; Freeman JW
Cancer Res; 2003 May; 63(10):2624-30. PubMed ID: 12750289
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of HDAC inhibitor-induced thrombocytopenia.
Matsuoka H; Unami A; Fujimura T; Noto T; Takata Y; Yoshizawa K; Mori H; Aramori I; Mutoh S
Eur J Pharmacol; 2007 Oct; 571(2-3):88-96. PubMed ID: 17628529
[TBL] [Abstract][Full Text] [Related]
9. Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines.
Osada H; Tatematsu Y; Sugito N; Horio Y; Takahashi T
Mol Carcinog; 2005 Dec; 44(4):233-41. PubMed ID: 16163707
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of histone deacetylase activity causes cell type-specific induction of the PDGF-B promoter only in the absence of activation by its enhancer.
Ullerås E; Miller SJ; Adam GI; Kanduri C; Wilcock AC; Franklin GC
Exp Cell Res; 2001 Nov; 270(2):188-98. PubMed ID: 11640883
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.
Yokota T; Matsuzaki Y; Miyazawa K; Zindy F; Roussel MF; Sakai T
Oncogene; 2004 Jul; 23(31):5340-9. PubMed ID: 15107822
[TBL] [Abstract][Full Text] [Related]
12. HDAC inhibitors TSA and sodium butyrate enhanced the human IL-5 expression by altering histone acetylation status at its promoter region.
Han S; Lu J; Zhang Y; Cheng C; Li L; Han L; Huang B
Immunol Lett; 2007 Feb; 108(2):143-50. PubMed ID: 17270283
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells.
Hou M; Wang X; Popov N; Zhang A; Zhao X; Zhou R; Zetterberg A; Björkholm M; Henriksson M; Gruber A; Xu D
Exp Cell Res; 2002 Mar; 274(1):25-34. PubMed ID: 11855854
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines.
Ou JN; Torrisani J; Unterberger A; Provençal N; Shikimi K; Karimi M; Ekström TJ; Szyf M
Biochem Pharmacol; 2007 May; 73(9):1297-307. PubMed ID: 17276411
[TBL] [Abstract][Full Text] [Related]
15. Effects of histone deacetylase inhibitors on the Ah receptor gene promoter.
Garrison PM; Rogers JM; Brackney WR; Denison MS
Arch Biochem Biophys; 2000 Feb; 374(2):161-71. PubMed ID: 10666294
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12,14-prostaglandin J2 through a histone deacetylase-independent mechanism.
Farrajota K; Cheng S; Martel-Pelletier J; Afif H; Pelletier JP; Li X; Ranger P; Fahmi H
Arthritis Rheum; 2005 Jan; 52(1):94-104. PubMed ID: 15641079
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells.
Li H; Wu X
Biochem Biophys Res Commun; 2004 Nov; 324(2):860-7. PubMed ID: 15474507
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of histone deacetylase inhibitors on phorbol ester- and TGF-beta1 induced murine tissue inhibitor of metalloproteinases-1 gene expression.
Young DA; Billingham O; Sampieri CL; Edwards DR; Clark IM
FEBS J; 2005 Apr; 272(8):1912-26. PubMed ID: 15819885
[TBL] [Abstract][Full Text] [Related]
19. IFI16 in human prostate cancer.
Alimirah F; Chen J; Davis FJ; Choubey D
Mol Cancer Res; 2007 Mar; 5(3):251-9. PubMed ID: 17339605
[TBL] [Abstract][Full Text] [Related]
20. A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells.
Hernandez M; Shao Q; Yang XJ; Luh SP; Kandouz M; Batist G; Laird DW; Alaoui-Jamali MA
Prostate; 2006 Aug; 66(11):1151-61. PubMed ID: 16652385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
